Sugi Predict

Sugi Predict / Compounds / SCHEMBL43410

SCHEMBL43410

SCHEMBL43410

NCc1ccc(CC(N)C(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.71
▸ PTGS1 P23219 3/20 0.70
▸ ALPI P09923 1/20 0.70
▸ PKM P14618 1/20 0.70
▸ XIAP P98170 1/20 0.70
▸ HIF1A Q16665 4/20 0.59
▸ ALOX15 P16050 3/20 0.59
▸ KDM4E B2RXH2 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ USP2 O75604 1/20 0.59
▸ EGFR P00533 1/20 0.59
▸ LCK P06239 1/20 0.59
▸ FYN P06241 1/20 0.59
▸ ADORA3 P0DMS8 1/20 0.59
▸ HTR2A P28223 1/20 0.59
▸ PTGS2 P35354 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ TPH1 P17752 1/20 0.59
▸ GRB2 P62993 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL662103 1.00 SLC7A5 (0.71) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL43411 1.00 SLC7A5 (0.71) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL366883 0.92 SLC7A5 (0.85) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.91 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL15656470 0.87 SLC7A5 (0.76) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL14233567 0.86 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL156189 0.85 SLC7A5 (0.74) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL837014 0.85 SLC7A5 (0.74) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL16581271 0.85 SLC7A5 (0.74) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL485684 0.85 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024030977-A2 NOVEL MELANOCORTIN ANALOGS SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) 2024-02-08 — — WO claimed
WO-2023084234-A1 ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS BICYCLETX LIMITED (GB) 2023-05-19 — — WO claimed
US-20220017572-A1 GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2022-01-20 — — US claimed
US-20210032304-A1 FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2021-02-04 — — US claimed
EP-3209682-B1 CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS MERCK SHARP & DOHME (US) 2020-12-30 — — EP claimed
EP-3752174-A1 FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF University of Florida Research Foundation, Incorporated (US) 2020-12-23 — — EP claimed
CN-111936157-A Fibroblast growth factor analogs and uses thereof 佛罗里达大学研究基金会 2020-11-13 — — CN claimed
CN-111132690-A Long-acting co-agonists of glucagon and GLP-1 receptor 默沙东公司 2020-05-08 — — CN claimed
US-20190255141-A1 GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES STICHTING KATHOLIEKE UNIVERSITEIT (NL) 2019-08-22 — — US claimed
WO-2019160910-A1 FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2019-08-22 — — WO claimed
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS RA PHARMACEUTICALS, INC. 2015-06-18 — — US claimed
US-20130109581-A1 POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS NOVARTIS AG (CH) 2013-05-02 — — US claimed
EP-2496947-A1 POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS Novartis AG (CH) 2012-09-12 — — EP claimed
US-20120040915-A1 PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-02-16 — — US claimed
WO-2011057029-A1 POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS NOVARTIS AG (CH) 2011-05-12 — — WO claimed
WO-2010088527-A2 PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2010-08-05 — — WO claimed
EP-0627925-A4 TRYPSIN INHIBITORS. CORVAS INT INC (US) 1997-07-30 — — EP claimed
US-5534498-A TREATMENT OF PANCREATITIS CORVAS INTERNATIONAL, INC. (US) 1996-07-09 — — US claimed
EP-0627925-A1 TRYPSIN INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1994-12-14 — — EP claimed
WO-1993014779-A1 TRYPSIN INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1993-08-05 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190255141-A1 GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES NGLY1, GRM3, NR0B2 SLC7A5 2764/4885PTGS1 1573/4885ALPI 3622/4885
US-20220017572-A1 GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES NGLY1, NR2C2, NR2E1 SLC7A5 2831/4885PTGS1 1612/4885ALPI 3410/4885
US-20150166606-A1 PEPTIDE AND PEPTIDOMIMETIC INHIBITORS KLKB1, KLK1, KLK5 SLC7A5 2730/4885PTGS1 1388/4885ALPI 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.